Par Net Receivables vs Accounts Payable Analysis

PAR Stock   294.05  12.65  4.50%   
Par Drugs financial indicator trend analysis is much more than just breaking down Par Drugs And prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Par Drugs And is a good investment. Please check the relationship between Par Drugs Net Receivables and its Accounts Payable accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Net Receivables vs Accounts Payable

Net Receivables vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Par Drugs And Net Receivables account and Accounts Payable. At this time, the significance of the direction appears to have strong relationship.
The correlation between Par Drugs' Net Receivables and Accounts Payable is 0.66. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Par Drugs And, assuming nothing else is changed. The correlation between historical values of Par Drugs' Net Receivables and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Par Drugs And are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Receivables i.e., Par Drugs' Net Receivables and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.66
Relationship DirectionPositive 
Relationship StrengthSignificant

Net Receivables

Accounts Payable

An accounting item on the balance sheet that represents Par Drugs obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Par Drugs And are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Par Drugs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Par Drugs And current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
As of November 23, 2024, Selling General Administrative is expected to decline to about 11.4 M. In addition to that, Tax Provision is expected to decline to about 29.1 M
 2021 2022 2023 2024 (projected)
Total Revenue742.0M951.0M956.4M669.2M
Depreciation And Amortization32.8M32.3M34.4M33.2M

Par Drugs fundamental ratios Correlations

-0.650.72-0.530.95-0.31-0.880.890.320.9-0.32-0.560.440.90.730.49-0.8-0.23-0.170.52-0.710.98-0.740.93-0.260.82
-0.65-0.410.94-0.850.760.87-0.7-0.22-0.680.760.230.02-0.68-0.81-0.590.930.740.01-0.950.98-0.780.96-0.8-0.18-0.88
0.72-0.41-0.230.67-0.22-0.570.590.660.53-0.23-0.350.450.530.810.3-0.590.15-0.190.23-0.470.72-0.510.74-0.380.42
-0.530.94-0.23-0.740.790.83-0.7-0.05-0.650.790.270.2-0.65-0.7-0.660.890.78-0.04-0.920.96-0.630.93-0.69-0.07-0.87
0.95-0.850.67-0.74-0.49-0.940.890.290.87-0.5-0.470.280.870.830.6-0.92-0.43-0.120.73-0.890.98-0.890.97-0.140.92
-0.310.76-0.220.79-0.490.71-0.58-0.32-0.581.00.190.15-0.58-0.63-0.380.760.78-0.1-0.770.75-0.430.79-0.44-0.22-0.62
-0.880.87-0.570.83-0.940.71-0.96-0.31-0.950.710.53-0.18-0.95-0.81-0.60.970.580.11-0.780.92-0.910.95-0.90.12-0.95
0.89-0.70.59-0.70.89-0.58-0.960.290.98-0.59-0.610.20.980.730.61-0.89-0.42-0.140.61-0.80.87-0.840.86-0.330.89
0.32-0.220.66-0.050.29-0.32-0.310.290.25-0.32-0.030.240.250.660.18-0.350.0-0.230.16-0.230.35-0.330.42-0.290.14
0.9-0.680.53-0.650.87-0.58-0.950.980.25-0.59-0.640.291.00.660.48-0.85-0.45-0.140.6-0.760.88-0.80.81-0.190.87
-0.320.76-0.230.79-0.51.00.71-0.59-0.32-0.590.20.14-0.59-0.63-0.380.770.78-0.1-0.770.76-0.440.79-0.45-0.21-0.63
-0.560.23-0.350.27-0.470.190.53-0.61-0.03-0.640.2-0.69-0.64-0.290.090.44-0.090.470.00.34-0.480.36-0.490.31-0.59
0.440.020.450.20.280.15-0.180.20.240.290.14-0.690.290.17-0.51-0.10.38-0.42-0.260.010.39-0.020.310.00.2
0.9-0.680.53-0.650.87-0.58-0.950.980.251.0-0.59-0.640.290.660.48-0.85-0.45-0.140.6-0.760.88-0.80.81-0.190.87
0.73-0.810.81-0.70.83-0.63-0.810.730.660.66-0.63-0.290.170.660.58-0.88-0.38-0.110.7-0.840.81-0.880.88-0.210.73
0.49-0.590.3-0.660.6-0.38-0.60.610.180.48-0.380.09-0.510.480.58-0.64-0.430.180.65-0.670.52-0.660.63-0.450.57
-0.80.93-0.590.89-0.920.760.97-0.89-0.35-0.850.770.44-0.1-0.85-0.88-0.640.60.12-0.840.97-0.870.98-0.90.1-0.94
-0.230.740.150.78-0.430.780.58-0.420.0-0.450.78-0.090.38-0.45-0.38-0.430.6-0.27-0.890.67-0.350.69-0.3-0.46-0.57
-0.170.01-0.19-0.04-0.12-0.10.11-0.14-0.23-0.14-0.10.47-0.42-0.14-0.110.180.12-0.270.170.05-0.110.06-0.180.2-0.21
0.52-0.950.23-0.920.73-0.77-0.780.610.160.6-0.770.0-0.260.60.70.65-0.84-0.890.17-0.90.65-0.90.650.260.77
-0.710.98-0.470.96-0.890.750.92-0.8-0.23-0.760.760.340.01-0.76-0.84-0.670.970.670.05-0.9-0.810.99-0.860.0-0.93
0.98-0.780.72-0.630.98-0.43-0.910.870.350.88-0.44-0.480.390.880.810.52-0.87-0.35-0.110.65-0.81-0.830.96-0.140.86
-0.740.96-0.510.93-0.890.790.95-0.84-0.33-0.80.790.36-0.02-0.8-0.88-0.660.980.690.06-0.90.99-0.83-0.860.03-0.92
0.93-0.80.74-0.690.97-0.44-0.90.860.420.81-0.45-0.490.310.810.880.63-0.9-0.3-0.180.65-0.860.96-0.86-0.310.88
-0.26-0.18-0.38-0.07-0.14-0.220.12-0.33-0.29-0.19-0.210.310.0-0.19-0.21-0.450.1-0.460.20.260.0-0.140.03-0.31-0.1
0.82-0.880.42-0.870.92-0.62-0.950.890.140.87-0.63-0.590.20.870.730.57-0.94-0.57-0.210.77-0.930.86-0.920.88-0.1
Click cells to compare fundamentals

Par Drugs Account Relationship Matchups

Par Drugs fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets601.2M763.8M786.9M888.7M1.0B763.9M
Short Long Term Debt Total231.3M115.8M60.1M83.2M74.9M139.5M
Other Current Liab2.5M19.7M42.0M59.0M21.0M20.4M
Total Current Liabilities108.4M159.8M148.6M139.9M124.4M123.4M
Total Stockholder Equity406.1M522.1M598.8M712.4M856.3M483.9M
Property Plant And Equipment Net351.4M343.7M343.5M386.9M413.3M305.2M
Net Debt(13.7M)(128.4M)(162.1M)(222.4M)(366.5M)(348.2M)
Retained Earnings175.3M291.3M368.0M481.6M625.5M656.8M
Accounts Payable62.0M67.2M106.6M80.9M53.6M75.1M
Cash73.8M211.6M162.1M222.4M366.5M384.9M
Non Current Assets Total359.0M352.0M351.3M394.3M419.9M311.6M
Non Currrent Assets Other7.1M8.2M7.6M7.3M6.4M6.3M
Other Assets7.1M7.6M7.6M7.3M8.4M5.1M
Cash And Short Term Investments73.8M211.6M162.1M222.4M366.5M384.9M
Net Receivables139.2M126.2M217.4M218.2M138.1M145.9M
Liabilities And Stockholders Equity601.2M763.8M786.9M888.7M1.0B763.9M
Non Current Liabilities Total86.6M81.9M39.6M36.4M35.4M33.6M
Inventory29.2M30.0M47.1M53.8M44.2M34.4M
Other Current Assets(1.0)35.1M9.1M(1K)372K353.4K
Other Stockholder Equity99.7M168.2M168.2M106.7M122.7M92.7M
Total Liab195.0M241.7M188.1M176.3M159.8M203.6M
Total Current Assets242.2M411.9M435.6M494.4M596.2M335.4M
Short Term Debt13.9M39.3M90K623K(51K)(48.5K)
Current Deferred Revenue30.0M46.5M90K623K51K48.5K
Other Liab37.5M40.4M38.0M39.5M45.5M41.5M
Net Tangible Assets290.3M406.1M522.1M598.8M688.6M433.3M
Net Invested Capital466.3M598.5M598.8M712.4M856.3M631.7M
Net Working Capital133.7M252.1M287.1M354.5M471.8M495.4M
Property Plant Equipment363.4M351.4M344.3M343.5M309.2M286.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Par Stock

Balance Sheet is a snapshot of the financial position of Par Drugs And at a specified time, usually calculated after every quarter, six months, or one year. Par Drugs Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Par Drugs and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Par currently owns. An asset can also be divided into two categories, current and non-current.